Evropská unie - čeština - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - lopinaviru, ritonavir - hiv infekce - antivirals for systemic use, protease inhibitors - kaletra je indikován v kombinaci s ostatními antiretrovirovými léčivými přípravky pro léčbu virus lidské imunodeficience (hiv-1) infikovaných dospělých, dospívajících a dětí ve věku od 14 dnů a více. volba přípravku kaletra k léčbě inhibitory proteázy hiv-1 infikovaných pacientů by měla být založena na individuálním testování virové rezistence a na posouzení předchozí léčby pacienta.

Evropská unie - čeština - EMA (European Medicines Agency)

hansa biopharma ab - imlifidase - desensitization, immunologic; kidney transplantation - imunosupresiva - idefirix is indicated for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. the use of idefirix should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients.

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

zentiva, k.s., praha array - 1057 pankreatin - enterosolventní tableta - 6000u - multienzymovÉ pŘÍpravky (lipasa, proteasa apod.)

Evropská unie - čeština - EMA (European Medicines Agency)

janssen-cilag international n.v. - daratumumab - mnohočetný myelom - monoclonal antibodies and antibody drug conjugates, antineoplastic agents - multiple myelomadarzalex is indicated: in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. v kombinaci s přípravkem bortezomib, thalidomid a dexametazon pro léčbu dospělých pacientů s nově diagnostikovaným mnohočetným myelomem, kteří nejsou způsobilí pro autologní transplantaci kmenových buněk. v kombinaci s lenalidomidem a dexamethasonem, nebo bortezomibu a dexametazonu, k léčbě dospělých pacientů s mnohočetným myelomem, kteří absolvovali alespoň jednu předchozí terapii. in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy (see section 5. jako monoterapie k léčbě dospělých pacientů s relabujícím a refrakterním mnohočetným myelomem, jejichž předchozí léčba zahrnovala proteazomový inhibitor a imunomodulační činidlo, a kteří prokázali progresi onemocnění při poslední terapii. al amyloidosisdarzalex is indicated in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain (al) amyloidosis.

Evropská unie - čeština - EMA (European Medicines Agency)

sanofi winthrop industrie - isatuximab - mnohočetný myelom - antineoplastická činidla - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.

Evropská unie - čeština - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - belantamab mafodotin - mnohočetný myelom - antineoplastická činidla - blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Evropská unie - čeština - EMA (European Medicines Agency)

stemline therapeutics b.v. - selinexor - mnohočetný myelom - antineoplastická činidla - nexpovio is indicatedin combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Evropská unie - čeština - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antineoplastická činidla - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Evropská unie - čeština - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - mnohočetný myelom - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Evropská unie - čeština - EMA (European Medicines Agency)

oncopeptides ab - melphalan flufenamide hydrochloride - mnohočetný myelom - antineoplastická činidla - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.